X11a is a neuronal adaptor protein that interacts with the amyloid precursor protein (APP) through a centrally located phosphotyrosine binding domain to inhibit the production of Ab peptide that is deposited in Alzheimer's disease brains. X11a also contains two C-terminal postsynaptic density-95, large discs, zona occludens 1 (PDZ) domains, and we show here that through its PDZ domains, X11a interacts with a novel transcription factor, fibrinogen silencer binding protein. Moreover, we show that an X11a/fibrinogen silencer binding protein complex signals to the nucleus to repress glycogen synthase kinase-3b promoter activity. Glycogen synthase kinase-3b is a favoured candidate kinase for phosphorylating tau in Alzheimer's disease. Our findings show a new function for X11a that may impact on Alzheimer's disease pathogenesis.
Introduction
Alzheimer's disease is characterized by two pathologies, amyloid plaques and neurofibrillary tangles. Amyloid plaques contain deposits of Ab peptide that is derived by a proteolytic cleavage from amyloid precursor protein (APP); neurofibrillary tangles comprise a hyperphosphorylated form of the microtubule-associated protein tau [1] .
X11a (also known as munc-18-interacting protein-1; mint1) is a member of a family of adaptor proteins that also includes X11b and X11g [2] . X11a binds to APP through a centrally located PTB domain and its overexpression inhibits Ab production [3] [4] [5] [6] . In addition to its PTB domain, X11a also contains a number of other proteinprotein interaction domains including two C-terminal PDZ domains through which it interacts with a number of other ligands [7] [8] [9] . Here, we show that through its PDZ domains, X11a also binds to the transcription factor, fibrinogen silencer binding protein (FSBP). Furthermore, we show that an X11a/FSBP complex acts to repress GSK3b gene promoter activity. GSK3b is a favoured candidate kinase for phosphorylating tau in Alzheimer's disease [10] . Thus, our results provide a new function for X11a and one that might impact on Alzheimer's disease pathogenesis.
Methods

Plasmids
Plasmids for X11a and FE65 were as described earlier [7, 8, 11] . Human FSBP cDNA was generated by PCR from a brain cDNA library and cloned into pCMV-Tag2 (Stratagene Cedar, Creek, Texas, USA) for FLAG-tagged expression in cells. X11a PDZ1 and PDZ2 domain 'wrecking' mutants were generated by mutating the key ILGV (residues 666-669 in PDZ1) and QLGF (residues 778-781 in PDZ2) to alanine. A glutathione S-transferase (GST)-FSBP fusion protein (GST-FSBP) was created by subcloning FSBP into pGEX-5X-1 (GE Healthcare, Piscataway, New Jersey, USA). Plasmids for quantifying APP intracellular domain (AICD)-dependent transcription and GSK3b promoter activities were as described earlier [11, 12] . Plasmids for X11a and FSBP fused to GAL4 DNA binding domain (GAL4DNAbd-X11a and GAL4DNAbd-FSBP) were created by subcloning of the X11a and FSBP cDNAs into the pM GAL4 fusion/expression vector. The transfection efficiency control vector plasmid pRL-TK was from Promega (Madison, Wisconsin, USA).
Yeast two-hybrid screen
The yeast two-hybrid library screen was performed as described earlier [8] .
Antibodies
A rabbit polyclonal FSBP antibody was generated by immunization with GST-FSBP. X11a was detected using a rabbit polyclonal antibody [7] or through the myc tag with antibody 9B11 (Cell Signalling Technology, Danvers, Massachusetts, USA). Presenilin was detected using PS1Ab [7] ; anti-c-Jun rabbit polyclonal antibody was from Santa Cellular, molecular and developmental neuroscience 761 Cruz (California, USA); anti-a-tubulin (DM1A) and anti-FLAG (M2) antibodies were from Sigma (St Louis, Missouri, USA).
Cell transfection and analyses
CHO and COS7 cells, and primary rat cortical neurons were cultured, transfected and analysed by SDS polyacrylamide gel electrophoresis and immunoblotting and by immunostaining as described earlier [11, 13, 14] . Similarly, cytosolic, membrane and nuclear fractions, and GST fusion pull-down and immunoprecipitation assays were performed as described earlier [7, 11] .
Luciferase reporter assays
Luciferase reporter assays for measuring GAL4-dependent and GSK3b promoter-dependent transcription in transfected CHO cells were performed as described earlier [11] . Transfection efficiencies were determined by cotransfection of pRL-TK plasmid that expresses Renilla luciferase. Statistical analyses involved one-way analysis of variance with least significant difference post-hoc test.
Northern analyses
Northern analyses were performed on a human multiple tissue Northern blot (Clontech, Mountain View, California, USA).
Results
To identify the proteins that interact with X11a, we screened a human brain yeast two-hybrid library with the X11a PDZ domains as 'bait'; PDZ domains are known mediators of protein-protein interactions [8] . We isolated a cDNA that encoded the C-terminal 189 amino acids of the uncharacterized transcription factor FSBP; FSBP has been described to downregulate transcription of the gchain of the human fibrinogen gene (Genbank AF007866). Northern blots showed that FSBP was encoded by a major mRNA species of approximately 7 kb, which was expressed in multiple tissues including the brain; a less abundant 9.5 kb species was also detected ( Fig. 1a ).
To confirm that X11a and FSBP interact and to determine which X11a PDZ domain mediates the interaction, we used GST fusion proteins containing both X11a PDZ domains (X11a-PDZ1 and PDZ2), the N-terminal PDZ domain (X11a-PDZ1) and the C-terminal PDZ domain (X11a-PDZ2), and used these as 'baits' in the pull-down assays from FLAG-FSBP transfected CHO cells. X11a-PDZ1 and X11a-PDZ2, but not X11a-PDZ1 or X11a-PDZ2 alone, interacted with FSBP in these assays (Fig. 1b ). We also created the GST-X11a-PDZ1 and GST-X11a-PDZ2 domain 'wrecking' mutants by altering key residues as described [9] and tested these for their ability to bind to FLAG-FSBP. Mutants in which either PDZ1 (X11a-PDZ1* and X11a-PDZ2*), PDZ2 (X11a-PDZ1* and X11a-PDZ2*) or both PDZ1 and PDZ2 together (X11a-PDZ1* and X11a-PDZ2*) were tested and again, X11a-PDZ1 and X11a-PDZ2 but not X11a-PDZ1* and X11a-PDZ2, X11a-PDZ1 and X11a-PDZ2* nor X11a-PDZ1* and X11a-PDZ2* bound to FLAG-FSBP ( Fig. 1c ).
We also generated a GST-FSBP fusion protein and used this in the pull-down assays from X11a transfected CHO cells. GST-FSBP but not GST alone bound to X11a in these assays (Fig. 1d ). Finally, as FSBP is a nuclear protein (see below; Fig. 2 ), we tested whether X11a binds to FSBP in immunoprecipitation assays from the nuclear fraction of X11a/FLAG-FSBP cotransfected cells and cortical neurons. FLAG-FSBP was immunoprecipitated from FLAG-FSBP + X11a or X11a-only transfected CHO cells by the M2 anti-FLAG antibody and the lysates probed with an anti-X11a antibody for the presence of X11a. This showed that X11a was present specifically in the FLAG-FSBP + X11a lysates ( Fig. 1e ). Similarly, endogenous FSBP and X11a were co-immunoprecipitated from nuclear lysate of cortical neurons ( Fig. 1f ). Thus, X11a binds FSBP in a variety of biochemical assays and this interaction requires both the X11a PDZ domains.
We next examined the subcellular location of X11a and FSBP in transfected COS-7 cells. We found that FSBP was present within the nucleus ( Fig. 2a ), which is consistent with its GenBank description as a gene silencer binding protein. X11a labelling was most intense in the perinuclear regions, consistent with earlier reports that showed it to be associated with the golgi and ER [15] . However, we observed a weaker but nevertheless consistent signal for X11a in the nuclei ( Fig. 2a ). To confirm the presence of X11a in the nuclei by another method, we prepared cytoplasmic, membrane and nuclear fractions from COS-7 cells transfected with X11a, FSBP or X11a + FSBP, and analysed expression of each protein by immunoblotting. FSBP was present exclusively in the nuclei, but while the majority of X11a was localized to the cytoplasmic/membrane fractions, a proportion (approximately 5%) was also present in the nuclei (Fig. 2b ). Cotransfection of FSBP with X11a did not noticeably alter the relative proportions of X11a in each compartment (Fig. 2b) .
In a similar manner, we examined the distribution of endogenous X11a and FSBP in cultured cortical neurons by preparing cytoplasmic/membrane and nuclear fractions and probing for each protein on immunoblots. Again, FSBP was present only in the nuclear fraction, but X11a was localized to both the cytoplasmic/membrane and nuclear factions (Fig. 2c ).
The C-terminal AICD has been shown to translocate to the nucleus with another PTB bearing adaptor protein FE65 and this AICD/FE65 complex has been proposed to regulate gene transcription [16] . We, therefore, enquired whether an AICD/X11a/FSBP complex might regulate transcription in a similar manner. To do so, we monitored the effects of X11a and/or FSBP on AICD-dependent transcription in transfected CHO cells. This involved the use of an assay described earlier in which a GAL4 DNAbinding domain-AICD fusion protein drives expression of a GAL4UAS luciferase reporter [12, 16] . Transfection of FE65, which is known to stimulate transcription in this assay, was used as a positive control [12, 16] . The presence of FE65 but not X11a stimulated transcription of the reporter as described earlier [16] , but neither FSBP nor X11a + FSBP stimulated transcription (Fig. 3a) .
In variations of the above assays, we also prepared GAL4 DNA-binding domain-X11a and -FSBP fusions and tested whether these were capable of activating transcription of the GAL4UAS reporter either alone, or with co-transfected X11a or FSBP. However, we detected no stimulation of transcription of the GAL4UAS reporter in any assay (Fig. 3b ). Thus, unlike AICD and FE65, X11a and FSBP do not seem to stimulate transcriptional activity in the GAL4 model systems.
One target for AICD-dependent transcription is the GSK3b gene [11, 17] ; GSK3b is a favoured candidate kinase for phosphorylating tau in Alzheimer's disease [10] . As X11a binds to AICD, and as we found it in the nucleus in association with FSBP, we therefore enquired whether X11a and/or FSBP might influence transcriptional activity of the GSK3b gene. To do so, we used a GSK3b promoter-luciferase reporter (GSK3b promoter-Luc) described [earlier 11]. Remarkably, we found that X11a and X11a + FSBP significantly inhibited GSK3b promoter activity by approximately 30 and 50%, respectively; FSBP alone had no effect on transcription (Fig. 3c ). As FSBP, but not X11a, is expressed in nontransfected CHO cells [7] , these results are consistent with the notion that the effect of X11a in X11a-only transfected cells is because of the presence of endogenous FSBP, and that the lack of effect of FSBP in FSBP-only transfected cells is because of the complete absence of X11a.
AICD has been shown to stimulate GSK3b promoter activity [11, 17] and so we considered whether the repression effect of X11a and FSBP was through some influence on APP signalling. We tested the effect of a mutant of X11a (involving a phenylalanine 608 to valine substitution in the PTB domain) that cannot bind APP on GSK3b promoter activity [18] . This mutant behaved identically to wild-type X11a (Fig. 3c) . In contrast, the mutation of PDZ1 and PDZ2 to abolish binding to FSBP (see Fig. 1c ), completely eliminated the effect of X11a/FSBP on GSK3b promoter activity (Fig. 3c) . Thus, X11a and FSBP repress GSK3b promoter activity and this inhibition requires an interaction between the two proteins but is not dependent on the binding of APP to the X11a PTB domain.
Discussion
Here, we show that through its two PDZ domains, X11a binds to the transcription factor FSBP and that FSBP and a proportion of X11a are present within the nuclei. Nuclear FSBP is in agreement with its description as a repressor protein (Genbank AF007866) and others have also shown the presence of X11 proteins in the nuclei [19] . Additional data suggest a role for X11a in nuclear signaling as it binds to CASK through N-terminal sequences [15] and CASK can function as a transcriptional co-activator of T-element containing genes with Tbr-1 [20] . Thus, our findings that FSBP and a proportion of X11a are present within the nuclei are consistent with other studies.
APP and FE65 have been shown to signal to the nucleus to stimulate expression of the responsive genes and X11a has an inhibitory role on APP/FE65 signalling [21] . We show here that an X11a/FSBP complex is unable to stimulate transcription of an AICD-dependent reporter and that neither X11a nor FSBP are transcriptionally competent in GAL4-dependent systems. Rather, we found that X11a and FSBP together inhibited transcription of the GSK3b promoter. There is evidence that the GSK3b gene is one target for APP/FE65 signalling [11, 17] . However, our results indicate that repression of the GSK3b promoter is distinct from this APP/FE65 signalling. Thus, while mutation of the X11a PDZ domains to eliminate binding to FSBP abolished X11a/FSBP repression, mutation of the X11a PTB domain to eliminate binding to APP had no effect on GSK3b promoter activity. Similarly, JIP1/APP transcriptional regulation is known to be distinct from that of FE65/APP [22] . Thus, there seem to be several different pathways by which APP and/or its associated proteins can regulate gene activity.
Binding of X11a to APP inhibits Ab production and as such, it has been suggested that X11a may be protective against Alzheimer's amyloid pathology [3] [4] [5] [6] . As GSK3b is implicated in tau hyperphosphorylation [10] , our finding that an X11a/FSBP complex inhibits GSK3b promoter activity suggests that it might also impact on Alzheimer's disease tau pathology. Fibrinogen silencer binding protein (FSBP) is a nuclear protein and a proportion of X11a is also located in the nucleus. (a) Shows confocal immunofluorescence labelling of COS-7 cells co-transfected with X11a (detected with rabbit anti-X11a) and FSBP (detected with mouse anti-FLAG). FSBP is present within the nucleus, and while the majority of X11a is cytoplasmic, a proportion is also seen in the nucleus (scale bar is 10 mm). (b) Shows immunoblots of soluble cytoplasmic (c) cytoplasmic membrane (m) and nuclear (n) fractions of X11a, FSBP and X11a + FSBP transfected COS7 cells as indicated. FSBP was detected using the FLAG tag; X11a using rabbit anti-X11a. The samples were also probed for tubulin, presenilin-1 (N-PS1) and c-Jun as fraction markers. (c) Shows immunoblots of combined cytoplasmic/membrane (c/m) and nuclear (n) fractions from 7-day-old rat cortical neurons probed for endogenous FSBP and X11a with rabbit anti-FSBP/anti-X11a antibodies as indicated. Markers for cytoplasm/membrane (c/m) and nuclei (n) were tubulin and c-Jun, respectively.
Conclusion
We show that a proportion of X11a is present in the nucleus where it binds to the repressor protein FSBP and that an X11a/FSBP complex represses the transcription of the GSK3â promoter. Our results show a novel role for X11a in nuclear signalling. 
